Edition:
India

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

19.37USD
19 Jan 2018
Change (% chg)

$-0.09 (-0.46%)
Prev Close
$19.46
Open
$19.41
Day's High
$19.45
Day's Low
$19.20
Volume
51,476
Avg. Vol
89,454
52-wk High
$19.94
52-wk Low
$12.06

Chart for

About

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $874.95
Shares Outstanding(Mil.): 46.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Amphastar Announces Approval For Sodium Nitroprusside Injection, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP

19 Dec 2017

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

30 Nov 2017

BRIEF-Amphastar Pharma reports results for three months ended Sept

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017

09 Nov 2017

BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

* Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

21 Sep 2017

BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04

* Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017

10 Aug 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

24 Jul 2017

Earnings vs. Estimates